Abstract:About 75% of breast carcinoma is invasive carcinoma of no special type (NST) and between 20%-30% of breast carcinoma is HER-2 positive. HER-2 overexpression now is a predictive factor for targeted therapy with anti-HER-2 agent like trastuzumab (herceptin). However, primary (de novo) resistance with trastuzumab occured in 65% patients and secondary resistance occured in 70% patients who have had good initial response. IGF-1R expression have been reported high in many malignancies including breast carcinoma. Res… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.